← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Asklepios Biopharmaceutical, Inc.
Chapel Hill, NC
$4,031,755
Total funding
5
Grants
Funding over time
peak $3M · FY2005–14$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$4,031,755 · 5
By mechanism
RC3$2,999,988 · 1
R43$440,760 · 2
U44$320,999 · 1
R41$270,008 · 1
Investigators at Asklepios Biopharmaceutical, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Self-Complementary AAV2 Factor IX for Hemophilia B$2,999,988
RC3 · FY2010 · HL
Preclinical Studies Supporting Phase Ib Study of Minidystrophin Gene in AAV Vecto$320,998
U44 · FY2008 · NS
Preclinical Development of AAV-Galanin for Epilepsy$283,690
R43 · FY2008 · NS
AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease$270,008
R41 · FY2014 · AG
rAAV Revitalized Structural Allografts$157,070
R43 · FY2005 · AR
Preclinical Studies Supporting Phase Ib Study of Minidystrophin Gene in AAV Vecto$1
U44 · FY2010 · NS